Key facts
- The NHMRC's interim guidelines advise conditional use of puberty suppressants for children under 18.
- The council rejected the "wait and see" model, stating withholding care can affect a young person's physical and mental health.
- The guidelines do not require a child to be distressed to be treated for gender incongruence.
- A multi-disciplinary team should be determined on a case-by-case basis, the advice states.
- Public consultation on the interim advice runs until January 18.
- The full guidelines, covering gender-affirming hormones, are expected in 2028.
Australia's National Health and Medical Research Council (NHMRC) released interim national clinical practice guidelines on Monday, November 16, 2026, advising that puberty blockers are appropriate for the gender-affirming care of young people in certain circumstances. The federal government commissioned the review last year after Queensland and the Northern Territory public hospitals banned the treatment, and New Zealand's government later followed despite opposition in the health sector.
The guidelines state that a child need not be distressed to be treated for gender incongruence, and that a multi-disciplinary team "should be determined on a case-by-case basis." Doctors should "prioritise the best interest and wellbeing of the young person and provide care that respects their autonomy," the advice reads. The council rejected alternative approaches such as the "wait and see" model, stating that withholding care "can affect the young person's physical and mental health, wellbeing, and ability to function."
The NHMRC describes gender incongruence as a difference between a person's gender and their sex recorded at birth, and states it is not a mental health disorder. Puberty blockers, which stop the body producing oestrogen and testosterone, have been used for conditions such as precocious puberty since the 1970s and in gender-affirming care since the 1990s. The advice largely aligns with the AusPATH Australian Standards of Care for Informed Consent Gender-Affirming Hormone Therapy.
The interim advice is based on recommendations from the council's multidisciplinary gender guideline development committee and is "supported by a systematic review of the evidence." Public consultation on the document, titled "Advice on the use of puberty suppressants in the care of trans and gender diverse people aged under 18," runs until January 18. The full guidelines, which will also address gender-affirming hormones, are expected in 2028.